|
Gene: GNAI2 |
Gene summary for GNAI2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | GNAI2 | Gene ID | 2771 |
Gene name | G protein subunit alpha i2 | |
Gene Alias | GIP | |
Cytomap | 3p21.31 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | B3KP24 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2771 | GNAI2 | P26T-E | Human | Esophagus | ESCC | 1.54e-14 | 2.84e-01 | 0.1276 |
2771 | GNAI2 | P27T-E | Human | Esophagus | ESCC | 3.00e-20 | 4.60e-01 | 0.1055 |
2771 | GNAI2 | P28T-E | Human | Esophagus | ESCC | 1.77e-22 | 6.22e-01 | 0.1149 |
2771 | GNAI2 | P30T-E | Human | Esophagus | ESCC | 9.23e-20 | 9.73e-01 | 0.137 |
2771 | GNAI2 | P31T-E | Human | Esophagus | ESCC | 2.05e-14 | 2.29e-01 | 0.1251 |
2771 | GNAI2 | P32T-E | Human | Esophagus | ESCC | 7.29e-34 | 8.33e-01 | 0.1666 |
2771 | GNAI2 | P36T-E | Human | Esophagus | ESCC | 2.28e-04 | 4.19e-01 | 0.1187 |
2771 | GNAI2 | P37T-E | Human | Esophagus | ESCC | 1.46e-36 | 1.01e+00 | 0.1371 |
2771 | GNAI2 | P38T-E | Human | Esophagus | ESCC | 1.78e-04 | 3.90e-01 | 0.127 |
2771 | GNAI2 | P39T-E | Human | Esophagus | ESCC | 8.18e-05 | 1.27e-01 | 0.0894 |
2771 | GNAI2 | P40T-E | Human | Esophagus | ESCC | 6.45e-14 | 6.79e-01 | 0.109 |
2771 | GNAI2 | P42T-E | Human | Esophagus | ESCC | 2.85e-17 | 5.58e-01 | 0.1175 |
2771 | GNAI2 | P44T-E | Human | Esophagus | ESCC | 6.65e-03 | 5.19e-01 | 0.1096 |
2771 | GNAI2 | P47T-E | Human | Esophagus | ESCC | 2.44e-16 | 3.89e-01 | 0.1067 |
2771 | GNAI2 | P48T-E | Human | Esophagus | ESCC | 1.82e-11 | 2.97e-01 | 0.0959 |
2771 | GNAI2 | P49T-E | Human | Esophagus | ESCC | 5.50e-06 | 1.09e+00 | 0.1768 |
2771 | GNAI2 | P52T-E | Human | Esophagus | ESCC | 4.22e-15 | 4.66e-01 | 0.1555 |
2771 | GNAI2 | P54T-E | Human | Esophagus | ESCC | 1.70e-10 | 4.38e-01 | 0.0975 |
2771 | GNAI2 | P56T-E | Human | Esophagus | ESCC | 8.86e-05 | 1.38e+00 | 0.1613 |
2771 | GNAI2 | P57T-E | Human | Esophagus | ESCC | 3.96e-05 | 2.54e-01 | 0.0926 |
Page: 1 2 3 4 5 6 7 8 9 10 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:200123314 | Breast | IDC | regulation of apoptotic signaling pathway | 82/1434 | 356/18723 | 6.27e-20 | 5.93e-17 | 82 |
GO:005134613 | Breast | IDC | negative regulation of hydrolase activity | 71/1434 | 379/18723 | 1.33e-12 | 2.90e-10 | 71 |
GO:200123414 | Breast | IDC | negative regulation of apoptotic signaling pathway | 49/1434 | 224/18723 | 1.45e-11 | 2.58e-09 | 49 |
GO:003166714 | Breast | IDC | response to nutrient levels | 62/1434 | 474/18723 | 2.33e-05 | 5.57e-04 | 62 |
GO:000758412 | Breast | IDC | response to nutrient | 29/1434 | 174/18723 | 5.69e-05 | 1.20e-03 | 29 |
GO:007259313 | Breast | IDC | reactive oxygen species metabolic process | 36/1434 | 239/18723 | 7.16e-05 | 1.43e-03 | 36 |
GO:00434348 | Breast | IDC | response to peptide hormone | 54/1434 | 414/18723 | 8.25e-05 | 1.61e-03 | 54 |
GO:005087813 | Breast | IDC | regulation of body fluid levels | 50/1434 | 379/18723 | 1.12e-04 | 2.10e-03 | 50 |
GO:003530414 | Breast | IDC | regulation of protein dephosphorylation | 18/1434 | 90/18723 | 1.39e-04 | 2.48e-03 | 18 |
GO:001095913 | Breast | IDC | regulation of metal ion transport | 52/1434 | 406/18723 | 1.76e-04 | 2.97e-03 | 52 |
GO:00703713 | Breast | IDC | ERK1 and ERK2 cascade | 43/1434 | 330/18723 | 4.28e-04 | 5.84e-03 | 43 |
GO:00459369 | Breast | IDC | negative regulation of phosphate metabolic process | 53/1434 | 441/18723 | 7.21e-04 | 8.79e-03 | 53 |
GO:00105639 | Breast | IDC | negative regulation of phosphorus metabolic process | 53/1434 | 442/18723 | 7.60e-04 | 9.25e-03 | 53 |
GO:003530813 | Breast | IDC | negative regulation of protein dephosphorylation | 9/1434 | 34/18723 | 8.01e-04 | 9.58e-03 | 9 |
GO:004366613 | Breast | IDC | regulation of phosphoprotein phosphatase activity | 12/1434 | 58/18723 | 1.27e-03 | 1.35e-02 | 12 |
GO:200037913 | Breast | IDC | positive regulation of reactive oxygen species metabolic process | 14/1434 | 76/18723 | 1.71e-03 | 1.67e-02 | 14 |
GO:00486592 | Breast | IDC | smooth muscle cell proliferation | 26/1434 | 184/18723 | 1.77e-03 | 1.72e-02 | 26 |
GO:00486602 | Breast | IDC | regulation of smooth muscle cell proliferation | 25/1434 | 180/18723 | 2.71e-03 | 2.41e-02 | 25 |
GO:0051924 | Breast | IDC | regulation of calcium ion transport | 32/1434 | 255/18723 | 3.94e-03 | 3.22e-02 | 32 |
GO:200037713 | Breast | IDC | regulation of reactive oxygen species metabolic process | 22/1434 | 157/18723 | 4.24e-03 | 3.31e-02 | 22 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501224 | Breast | IDC | Parkinson disease | 107/867 | 266/8465 | 2.57e-39 | 8.36e-37 | 6.26e-37 | 107 |
hsa0491523 | Breast | IDC | Estrogen signaling pathway | 35/867 | 138/8465 | 2.55e-07 | 5.18e-06 | 3.88e-06 | 35 |
hsa0472323 | Breast | IDC | Retrograde endocannabinoid signaling | 31/867 | 148/8465 | 7.62e-05 | 7.50e-04 | 5.61e-04 | 31 |
hsa0516324 | Breast | IDC | Human cytomegalovirus infection | 39/867 | 225/8465 | 6.66e-04 | 5.41e-03 | 4.05e-03 | 39 |
hsa0497122 | Breast | IDC | Gastric acid secretion | 16/867 | 76/8465 | 3.80e-03 | 2.33e-02 | 1.74e-02 | 16 |
hsa0467024 | Breast | IDC | Leukocyte transendothelial migration | 21/867 | 114/8465 | 5.41e-03 | 3.13e-02 | 2.34e-02 | 21 |
hsa0517014 | Breast | IDC | Human immunodeficiency virus 1 infection | 33/867 | 212/8465 | 9.28e-03 | 4.37e-02 | 3.27e-02 | 33 |
hsa0501234 | Breast | IDC | Parkinson disease | 107/867 | 266/8465 | 2.57e-39 | 8.36e-37 | 6.26e-37 | 107 |
hsa0491533 | Breast | IDC | Estrogen signaling pathway | 35/867 | 138/8465 | 2.55e-07 | 5.18e-06 | 3.88e-06 | 35 |
hsa0472333 | Breast | IDC | Retrograde endocannabinoid signaling | 31/867 | 148/8465 | 7.62e-05 | 7.50e-04 | 5.61e-04 | 31 |
hsa0516334 | Breast | IDC | Human cytomegalovirus infection | 39/867 | 225/8465 | 6.66e-04 | 5.41e-03 | 4.05e-03 | 39 |
hsa0497132 | Breast | IDC | Gastric acid secretion | 16/867 | 76/8465 | 3.80e-03 | 2.33e-02 | 1.74e-02 | 16 |
hsa0467034 | Breast | IDC | Leukocyte transendothelial migration | 21/867 | 114/8465 | 5.41e-03 | 3.13e-02 | 2.34e-02 | 21 |
hsa0517015 | Breast | IDC | Human immunodeficiency virus 1 infection | 33/867 | 212/8465 | 9.28e-03 | 4.37e-02 | 3.27e-02 | 33 |
hsa0501243 | Breast | DCIS | Parkinson disease | 106/846 | 266/8465 | 1.64e-39 | 5.29e-37 | 3.90e-37 | 106 |
hsa0491542 | Breast | DCIS | Estrogen signaling pathway | 35/846 | 138/8465 | 1.40e-07 | 2.51e-06 | 1.85e-06 | 35 |
hsa0472342 | Breast | DCIS | Retrograde endocannabinoid signaling | 29/846 | 148/8465 | 2.82e-04 | 2.34e-03 | 1.72e-03 | 29 |
hsa0516344 | Breast | DCIS | Human cytomegalovirus infection | 38/846 | 225/8465 | 8.11e-04 | 5.95e-03 | 4.38e-03 | 38 |
hsa0497142 | Breast | DCIS | Gastric acid secretion | 16/846 | 76/8465 | 2.97e-03 | 1.81e-02 | 1.33e-02 | 16 |
hsa0467044 | Breast | DCIS | Leukocyte transendothelial migration | 21/846 | 114/8465 | 4.07e-03 | 2.31e-02 | 1.70e-02 | 21 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GNAI2 | SNV | Missense_Mutation | novel | c.889T>C | p.Tyr297His | p.Y297H | P04899 | protein_coding | deleterious(0.01) | probably_damaging(0.959) | TCGA-5T-A9QA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | SD |
GNAI2 | SNV | Missense_Mutation | c.109N>A | p.Leu37Met | p.L37M | P04899 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-BH-A0DL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR | |
GNAI2 | SNV | Missense_Mutation | c.292N>T | p.Pro98Ser | p.P98S | P04899 | protein_coding | tolerated(0.37) | benign(0.005) | TCGA-BH-A1FJ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
GNAI2 | SNV | Missense_Mutation | novel | c.706N>T | p.Ala236Ser | p.A236S | P04899 | protein_coding | tolerated(0.38) | benign(0.115) | TCGA-S3-AA15-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
GNAI2 | deletion | Frame_Shift_Del | novel | c.406delN | p.Gly136ValfsTer22 | p.G136Vfs*22 | P04899 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
GNAI2 | SNV | Missense_Mutation | rs781807470 | c.475N>A | p.Asp159Asn | p.D159N | P04899 | protein_coding | tolerated(0.19) | benign(0.003) | TCGA-C5-A1ME-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
GNAI2 | SNV | Missense_Mutation | rs781986131 | c.200G>A | p.Arg67Gln | p.R67Q | P04899 | protein_coding | tolerated(0.39) | benign(0.006) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
GNAI2 | SNV | Missense_Mutation | c.1055N>A | p.Cys352Tyr | p.C352Y | P04899 | protein_coding | tolerated(0.06) | possibly_damaging(0.776) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD | |
GNAI2 | SNV | Missense_Mutation | c.878N>A | p.Gly293Glu | p.G293E | P04899 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
GNAI2 | SNV | Missense_Mutation | rs782786744 | c.979G>A | p.Ala327Thr | p.A327T | P04899 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AZ-4313-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |